



DESCRIPTION


Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera His-tag Alexa Fluor® 647

Catalog Number: AFR357

Source	Mouse myeloma cell line, NS0-derived human VEGFR2/KDR/Flk-1 protein			
	Human VEGFR2 (Ala20-Glu764) Accession # AAC16450.1	IEGRMD	Human IgG ₁ (Pro100-Lys330)	6-His tag
	N-terminus C-termin			
N-terminal Sequence Analysis	a Ala20			
Structure / Form	Disulfide-linked homodimer Labeled with Alexa Fluor® 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm			
Predicted Molecular Mass	110 kDa (monomer)			
SPECIFICATIONS				
SDS-PAGE	150-170 kDa, under reducing conditions.			
Activity	Measured by flow cytometry for its ability to bind Human VEGFR2/KDR/Flk-1 Antibody conjugated fluorescent beads at 2.50-10.0 μg/mL (100 μL/well). Please Note: Optimal dilutions should be determined by each laboratory for each application.			
Endotoxin Level	<1.0 EU per 1 µg of the protein by the LAL method.			
Purity	>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.			
Formulation	Supplied as a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.			







BACKGROUND

PREPARATION AND STORAGE

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PIGF and VEGF with high affinity, VEGFR2 binds VEGF but not PIGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References:

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Rev. 12/14/2022 Page 1 of 2





Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera His-tag Alexa Fluor® 647

Catalog Number: AFR357

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.



